Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

47.63 -0.90 (-1.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 628,561
Open 48.88
Bid (Size) 40.06 (1)
Ask (Size) 49.50 (2)
Prev. Close 48.53
Today's Range 47.23 - 49.09
52wk Range 29.02 - 58.38
Shares Outstanding 79,225,276
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PTC THERAPEUTICS INC (NASDAQ:PTCT) - A Biotech Stock With Strong Growth and Reasonable Valuation
PTC THERAPEUTICS INC (NASDAQ:PTCT) offers strong growth potential with reasonable valuation, supported by solid financial health and profitability metrics. A biotech stock worth watching. 
Via Chartmill
PTC THERAPEUTICS INC (NASDAQ:PTCT) – A Strong Growth Stock with Technical Breakout Potential
PTC THERAPEUTICS INC (NASDAQ:PTCT) shows strong growth fundamentals and a promising technical breakout pattern, making it a stock to watch for growth investors. 
Via Chartmill

Performance

YTD
+3.8%
+3.8%
1 Month
-6.3%
-6.3%
3 Month
+0.5%
+0.5%
6 Month
+10.6%
+10.6%
1 Year
+39.3%
+39.3%

More News

Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
Earnings Scheduled For May 6, 2025
Via Benzinga
PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
PTC THERAPEUTICS INC (NASDAQ:PTCT) - A Biotech Stock With Strong Growth and Reasonable Valuation
Via Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
PTC THERAPEUTICS INC (NASDAQ:PTCT) - A Biotech Stock With Strong Growth and Reasonable Valuation
Via Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
This National Vision Holdings Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday
Via Benzinga
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Via Benzinga
PTC Therapeutics (PTCT) Q1 2025 Earnings Call
Via The Motley Fool
Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal?
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga

Frequently Asked Questions

Is PTC Therapeutics, Inc. - Common Stock publicly traded?
Yes, PTC Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does PTC Therapeutics, Inc. - Common Stock trade on?
PTC Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for PTC Therapeutics, Inc. - Common Stock?
The ticker symbol for PTC Therapeutics, Inc. - Common Stock is PTCT on the Nasdaq Stock Market
What is the current price of PTC Therapeutics, Inc. - Common Stock?
The current price of PTC Therapeutics, Inc. - Common Stock is 47.63
When was PTC Therapeutics, Inc. - Common Stock last traded?
The last trade of PTC Therapeutics, Inc. - Common Stock was at 07/18/25 04:00 PM ET
What is the market capitalization of PTC Therapeutics, Inc. - Common Stock?
The market capitalization of PTC Therapeutics, Inc. - Common Stock is 3.77B
How many shares of PTC Therapeutics, Inc. - Common Stock are outstanding?
PTC Therapeutics, Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.